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Abstract
Background: Simvastatin has been shown to ameliorate pulmonary hypertension by several
mechanisms in experimental animal models. In this study, we hypothesized that the major benefits
of simvastatin in pulmonary hypertension occur via the heme oxygenase-1 pathway.
Methods: Simvastatin (10 mg/kgw/day) was tested in two rat models of pulmonary hypertension
(PH): monocrotaline administration and chronic hypoxia. The hemodynamic changes, right heart
hypertrophy, HO-1 protein expression, and heme oxygenase (HO) activity in lungs were measured
in both models with and without simvastatin treatment. Tin-protoporphyrin (SnPP, 20 μmol/kg w/
day), a potent inhibitor of HO activity, was used to confirm the role of HO-1.
Results: Simvastatin significantly ameliorated pulmonary arterial hypertension from 38.0 ± 2.2 mm
Hg to 22.1 ± 1.9 mm Hg in monocrotaline-induced PH (MCT-PH) and from 33.3 ± 0.8 mm Hg to
17.5 ± 2.9 mm Hg in chronic hypoxia-induced PH (CH-PH) rats. The severity of right ventricular
hypertrophy was significantly reduced by simvastatin in MCT-PH and CH-PH rats. Co-
administration with SnPP abolished the benefits of simvastatin. Simvastatin significantly increased
HO-1 protein expression and HO activity in the lungs of rats with PH; however co-administration
of SnPP reduced HO-1 activity only. These observations indicate that the simvastatin-induced
amelioration of pulmonary hypertension was directly related to the activity of HO-1, rather than
its expression.
Conclusion:  This study demonstrated that simvastatin treatment ameliorates established
pulmonary hypertension primarily through an HO-1-dependent pathway.
Background
Pulmonary hypertension (PH) is a rare but life-threaten-
ing disease characterized by significant increases in pul-
monary arterial pressure (PAP) and right ventricular
hypertrophy (RVH).[1] It is a disease of the small pulmo-
nary arteries that results in a progressive increase in pul-
monary vascular resistance and, ultimately, right
ventricular failure and death.
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Simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A
(HMG-CoA) reductase inhibitor, is a statin, agents with
well-known lipid-lowering effects that substantially
decrease cardiovascular morbidity and mortality in
patients with and without coronary artery diseases.[2,3]
However, a growing body of evidence has revealed that
the therapeutic benefits of statins cannot be explained
solely by their inhibitory action on cholesterol synthe-
sis.[4,5] These so-called pleiotropic, cholesterol-inde-
pendent effects are believed to include anti-proliferative,
anti-inflammatory, and antioxidant actions. Today, a
number of experimental studies suggest the potential of
statins as a novel therapy for PH, based on these pleio-
tropic effects.[6] Several experimental studies have inves-
tigated the possible mechanisms of simvastatin benefits in
models of PH induced by monocrotaline (MCT) or by
chronic hypoxia (CH). [7-9] However, the underlying
mechanism of these protective effects of simvastatin in PH
remains to be investigated.
Heme oxygenase (HO) is the rate-limiting enzyme in the
oxidation of heme to biliverdin and carbon monoxide
(CO). There are three isoenzymes of HO: HO-1, an induc-
ible isoform, and HO-2 and HO-3, which are constitu-
tively synthesized. Induction of the important
cytoprotective molecule HO-1 has been shown to have
vasodilatory, anti-inflammatory, and pro-apoptotic
effects mediated through CO and bilirubin.[10,11] HO-1
expression is upregulated in several pulmonary diseases
and can be induced by simvastatin treatment.[12] Previ-
ous studies have shown that raising endogenous HO-1
levels prevented CH-induced PH (CH-PH), and that HO-
1 transgenic mice were protected from the development of
PH and vessel wall hypertrophy induced by CH.[13,14]
Moreover, HO-1 is a target site of statins in endothelial
cells leading to HO-1 promoter activation, transcript and
protein accumulation.[15] Simvastatin activates HO-1
expression through p38 and the phosphoinositide 3-
kinase-Akt pathways which mediate its anti-inflammatory
and anti-proliferative effects in vitro and in vivo.[16] Pre-
viously, our research group has also demonstrated that
simvastatin could protect the liver from ischemia-reper-
fusion injury by HO-1 induction.[17] Therefore, we
hypothesized here that simvastatin therapy could amelio-
rate PH severity in MCT-induced PH (MCT-PH) and CH-
PH in the rat, and that HO-1 dependent pathways would
be important mechanisms of the protective effects of sim-
vastatin.
Methods
Animal Treatments and Groups
Female Wistar rats weighing between 200 and 250 g were
used in our experiments. All animal care and experiments
were performed in accordance with the Guide for the Care
and Use of Animals (National Academy Press, Washing-
ton, DC, 1996). All protocols used in this study were
approved by the Laboratory Animal Care Committee of
National Taiwan University College of Medicine.
Pulmonary Hypertension Animal Models
Rats in the MCT-PH groups were subcutaneously injected
with monocrotaline (MCT, 60 mg/kg of body weight
(kgw); Sigma-Aldrich, St. Louis, MO) on day 1. For 24
days, rats in the CH-PH groups were placed in an altitude
chamber (hypobaric chamber) from 5 p.m. to 8 a.m. each
day (intermittent exposure) and breathed air at normal
(sea level) air pressure the rest of the time.[18] A simu-
lated altitude of 5,500 m (380 torr) was selected because
it represents the maximal altitude to which most rats can
successfully adapt. Food and water were freely available at
all times, and the animals were maintained at a constant
temperature on a normal light cycle.
Drug Treatment
Simvastatin (10 mg/kgw; Calbiochem, San Diego, CA)
was given daily by intraperitoneal (i.p.) injection for three
days (days 21~23). Simvastatin was prepared as a solution
in ethanol and then activated by alkaline hydrolysis. The
final concentration was 5 mg/ml. Rats in the normal con-
trol group received only the same volume of solvent vehi-
cle without simvastatin. Tin-protoporphyrin IX (SnPP, 20
μmol/kgw; Porphyrin Products, Inc., Logan, UT) was
given by subcutaneous injection (s.c) on day 21~23 to
inhibit HO activity. (Figure 1)
Animal Groups
The experimental animals were divided into the following
10 groups (each group n ≥ 4, see Table 1): normal control
(N), normal + simvastatin treatment (NS), monocrotaline
treatment (M), monocrotaline + simvastatin treatment
(MS), monocrotaline + simvastatin + SnPP treatment
(MSP), monocrotaline + SnPP treatment (MP), chronic
hypoxia (H), chronic hypoxia + simvastatin treatment
(HS), chronic hypoxia + simvastatin + SnPP treatment
(HSP), chronic hypoxia + SnPP treatment (HP).
Measurement of Pulmonary Arterial Pressure
On day 24, rats were anesthetized with pentobarbital (35
mg/kgw, i.p. injection). Tracheal cannulation was per-
formed after tracheostomy. The chest was opened via a
midline incision, and the animal was ventilated by a ven-
tilator with room air (70 strokes/min, tidal volume 10 ml/
kg), with about 2–3 cm H2O positive end expiratory pres-
sure (PEEP). The right ventricle outflow tract was directly
punctured by a polyethylene tubing PE-10 tube. Subse-
quently, a silastic catheter was inserted via the marks cre-
ated by the puncture wound to monitor pulmonary artery
blood pressure. Polyethylene cannulas were placed in the
left femoral vein for infusion of saline at 1.2 ml per hour,Respiratory Research 2009, 10:32 http://respiratory-research.com/content/10/1/32
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the left femoral artery for blood sampling, and the left
carotid artery for measurement of mean arterial pressure.
Western Blot Analysis
For detection of HO-1 immunoreactive proteins, lung tis-
sues from each group were homogenized in T-PER tissue
protein extraction buffer (Pierce, Rockford, IL) containing
protease inhibitors. The lysates were separated by 12%
sodium dodecyl sulfate-polyacrylamide gel electrophore-
sis and then blotted and stained with HO-1 antibody
(OSA-111; StressGen, Victoria, B.C., Canada) following
procedures previously described.[17] Protein signal quan-
tification was performed by computer-assisted densitom-
etry (Gel Pro 3.1; Media Cybernetics, Bethesda, MD).
HO Activity Assay
HO activity in lung cells of each group was measured by
the generation of bilirubin. [19-21] Briefly, microsomes
from lung tissue were added to a reaction mixture contain-
ing NADPH, rat liver cytosol as a source of biliverdin
Schematic outline of the experimental protocol Figure 1
Schematic outline of the experimental protocol. Monocrotaline-induced pulmonary hypertension (MCT-PH) was estab-
lished by subcutaneous administration on day 1 (60 mg/kgw), and chronic hypoxia-induced pulmonary hypertension (CH-PH) 
was established by treatment in a hypobaric chamber (380 Torr, intermittent exposure) for 24 days. Simvastatin was given by 
intraperitoneal injection (10 mg/kgw/day) on day 21~23, and SnPP (20 μmol/kgw/day) was injected alone or with simvastatin 
simultaneously on days 21~23. All animals underwent experimental surgery on day 24.
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: Pulmonary hypertension rat models and pharmacologic treatment in the ten experimental groups
Group (Abbreviation) Treatment
Normal control (N) Sham
Normal+Simvastatin (NS) Simvastatin on days 21~23
MCT (M) MCT on day 1
MCT+Simvastatin (MS) MCT on day 1; simvastatin on days 21~23
MCT+Simvastatin+SnPP (MSP) MCT on day 1; co-treated with simvastatin and SnPP on days 21~23
MCT+SnPP (MP) MCT on day 1; SnPP on days 21~23
Chronic Hypoxia (H) Placed in a hypobaric chamber for 24 days
Chronic Hypoxia+Simvastatin (HS) Chronic hypoxia for 24 days, simvastatin on days 21~23
Chronic Hypoxia+Simvastatin+SnPP (HSP) Chronic hypoxia for 24 days, co-treated with simvastatin and SnPP on days 21~23
Chronic Hypoxia+SnPP (HP) Chronic hypoxia, SnPP on days 21~23Respiratory Research 2009, 10:32 http://respiratory-research.com/content/10/1/32
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reductase, and the substrate hemin. The reaction was con-
ducted at 37°C in the dark for 1 hr and terminated by the
addition of 0.5 mL of chloroform, and the extracted
bilirubin was calculated by the difference in absorbance
between 460 and 530 nm with an extinction coefficient of
40 mM-1cm-1. The HO activity was expressed as picomoles
per hour per milligram of protein, and then normalized to
the control group.
Immunohistochemistry
Four-micrometer lung sections were deparaffinized in
xylene and then rehydrated in graded alcohol solutions.
To determine the distribution of HO-1 protein, the lung
sections were incubated with the OSA-111 HO-1 antibody
(StressGen). The detailed procedure was as previously
described.[17]
Statistical Methods
Data are expressed as means ± S.E. Statistical analysis was
performed using Sigma Stat software (Jandel Scientific,
San Raphael, CA) by unpaired Student's t-test for compar-
isons between 2 groups, and by one-way analysis of vari-
ance (ANOVA) for comparisons between >2 groups. A p
value < 0.05 was regarded as significant.
Results
Two Rat Models of Pulmonary Hypertension
MCT administration (M group) significantly increased the
PAP (38.0 ± 2.2 mm Hg) on day 24 compared with the
normal control group (16.7 ± 0.6 mm Hg for N group, p <
0.05, Figure 2A). Twenty-four days of CH (H group) also
induced a significant increase in PAP (33.3 ± 0.8 mm Hg,
p < 0.05 versus N group, Figure 2B). However, there was
no significant difference in PAP between the MCT and CH
groups. In addition, no significant change in systemic
blood pressure was found between the normal control (N
group) and the MCT or CH groups (data not shown).
Simvastatin Ameliorated Established Pulmonary 
Hypertension
In preliminary experiments, we treated PH rats with simv-
astatin for 1, 2, and 3 days and examined the severity of
pulmonary hypertension. Established pulmonary hyper-
tension induced by both MCT and CH were significantly
decreased by 3 days of simvastatin treatment but not by
treatment for 1 or 2 days (data not shown). After 3 days of
treatment (days 21 ~23) with simvastatin (10 mg/kgw,
i.p.) in MCT-PH rats (MS group), the PAP measured on
day 24 was significantly decreased to 22.1 ± 1.9 mm Hg (p
< 0.05 vs M group, Figure 2A). In CH-PH rats, 3-day
administration of simvastatin (HS group) significantly
decreased the PAP (17.5 ± 2.9 mm Hg) on day 24 com-
pared with CH-PH rats (H group, p < 0.05, Figure 2B).
However, there was no change in systemic blood pressure
before and after simvastatin treatment in these groups
(data not shown).
Co-treatment with SnPP and Simvastatin Maintained High 
Pulmonary Arterial Pressure
To investigate the role of HO-1 in the pulmonary arterial
pressure lowering effect of simvastatin treatment, the
heme oxygenase (HO) activity competitive inhibitor,
SnPP (20 μmol/kgw, s.c, on day 21~23), was adminis-
tered alone or simultaneously with simvastatin to MCT-
PH and CH-PH rats. MCT-PH rats given SnPP alone (MP
group) maintained a high PAP (32.4 ± 0.9 mm Hg, Figure
2A). Co-administration of simvastatin and SnPP in MCT-
PH rats (MSP group) significantly abolished the effects of
simvastatin (31.5 ± 2.7 mm Hg, p < 0.05 versus the MS
group, Figure 2A). In the CH-PH rats group, the PAP after
SnPP treatment (HP group) was 36.0 ± 1.4 mm Hg (Figure
2B). Although simvastatin treatment could decrease PAP
in rats with chronic hypoxia (HS group, Figure 2B), co-
treatment with SnPP (HSP group) abolished the simvasta-
tin effect (31.8 ± 3.1 mm Hg for HSP group, p < 0.05 ver-
sus the HS group, Figure 2B). Co-treatment with SnPP did
not change the systemic blood pressure in these groups
(data not shown). The PAP lowering effects of simvastatin
in MCT-PH and CH-PH rats were suppressed by co-treat-
ment with the HO inhibitor, SnPP.
Effect of Simvastatin on Right Ventricular Hypertrophy
Right ventricular hypertrophy (RVH) is a hallmark of PH.
The ratio of right ventricular to left ventricular plus sep-
tum weight (RV/LV+S) is a commonly used indicator of
the severity of PH. In this study, the RV/LV+S ratios in
MCT-PH (0.42 ± 0.01) and CH-PH (0.51 ± 0.005) rats
were both significantly higher than in normal control
(0.30 ± 0.004; both M:N and H:N p < 0.05, Figure 3). After
three days of simvastatin treatment, the RV/LV+S ratio fell
significantly to 0.36 ± 0.009 (MS group; p < 0.05 versus
the M group, Figure 3A) and 0.47 ± 0.011 (HS group; p <
0.05 versus the H group, Figure 3B). These data showed
that simvastatin treatment could significantly decrease the
RV/LV+S ratio in PH rats, resulting from a reduction in
right ventricular work.
SnPP Suppressed the Ameliorative Effect of Simvastatin on 
RVH
Rats co-treated with simvastatin and SnPP in both MCT-
PH and CH-PH protocols maintained high RV/LV+S
ratios. The RV/LV+S ratio was 0.47 ± 0.009 in the MSP
group (p < 0.05 versus MS group, Figure 3A) and 0.52 ±
0.017 in the HSP group (p < 0.05 versus the HS group, Fig-
ure 3B).
Effect of Simvastatin on HO-1 Protein Expression in Lung
To investigate the relationship between HO-1 expression
and the simvastatin attenuation of established PH, weRespiratory Research 2009, 10:32 http://respiratory-research.com/content/10/1/32
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Effects of simvastatin and SnPP on pulmonary arterial pressure in MCT-PH (A) and CH-PH (B) rats Figure 2
Effects of simvastatin and SnPP on pulmonary arterial pressure in MCT-PH (A) and CH-PH (B) rats. Rats that 
received simvastatin (MS and HS groups) had significantly decreased pulmonary arterial pressure compared with non-simvasta-
tin treated PH rats (M and H groups). Co-treatment with simvastatin and SnPP (MSP and HSP groups) failed to relieve the high 
pulmonary arterial pressure. Rats that received SnPP alone (MP and HP groups) maintained high pulmonary arterial pressure. 
Horizontal bars indicate groups that differed significantly from each other, * p < 0.05. (N = normal control, M = monocrotaline 
treatment, MS = monocrotaline + simvastatin treatment, MSP = monocrotaline + simvastatin + SnPP treatment, MP = 
monocrotaline + SnPP treatment, H = chronic hypoxia, HS = chronic hypoxia + simvastatin treatment, HSP = chronic hypoxia 
+ simvastatin + SnPP treatment, HP = chronic hypoxia + SnPP treatment).Respiratory Research 2009, 10:32 http://respiratory-research.com/content/10/1/32
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The effects of simvastatin and SnPP on right ventricular hypertrophy in MCT-PH (A) and CH-PH (B) rats Figure 3
The effects of simvastatin and SnPP on right ventricular hypertrophy in MCT-PH (A) and CH-PH (B) rats. Sim-
vastatin treatment (MS and HS groups) prevented progression and improved established right ventricular hypertrophy com-
pared with the non-simvastatin treated PH rats (M and H groups). Rats that received SnPP alone (MP and HP groups) or 
received both simvastatin and SnPP (MSP and HSP groups) developed severe right ventricular hypertrophy. The index of right 
ventricular hypertrophy is given as the ratio of right ventricle to (left ventricle plus septum) weight [RV/(LV+S)]. Horizontal 
bars indicate groups that differed significantly from each other, * p < 0.05. (N = normal control, M = monocrotaline treatment, 
MS = monocrotaline + simvastatin treatment, MSP = monocrotaline + simvastatin + SnPP treatment, MP = monocrotaline + 
SnPP treatment, H = chronic hypoxia, HS = chronic hypoxia + simvastatin treatment, HSP = chronic hypoxia + simvastatin + 
SnPP treatment, HP = chronic hypoxia + SnPP treatment).
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examined the level and distribution of HO-1 protein in rat
lung. HO-1 protein expression increased after simvastatin
treatment in the normal control group (NS group, Figure
4). In MCT-PH and CH-PH rats, simvastatin administra-
tion led to significantly higher levels of HO-1 protein
expression, of 310 ± 40% (MS group, p < 0.05 versus M
group, Figure 4A) and 420 ± 130% (HS group, p < 0.05
versus H group, Figure 4B). Interestingly, treatment of PH
rats with SnPP alone (MP and HP groups) or co-adminis-
tration of SnPP and simvastatin (MSP and HSP groups)
also significantly increased HO-1 protein expression (p <
0.05 for MP group vs. M group, MSP group vs. M group,
HP group vs. H group, and HSP group vs. H group). Fur-
thermore, immunohistochemical staining revealed that
the distribution of HO-1 protein expression increased
around the pulmonary vascular sites after simvastatin
treatment (Figure 5).
Effect of Simvastatin on Heme Oxygenase Activity in Rat 
Lung
The effect of simvastatin treatment on heme oxygenase
(HO) activity in rat lung was measured, based on
bilirubin generation. The bilirubin concentration in each
group was normalized to that of the normal control
group. In MCT-PH and CH-PH rats, simvastatin treatment
caused a significant elevation in HO activity from 130 ±
50% of control (M group) to 280 ± 50% of control (MS
group, p < 0.05 vs. M group, Figure 6A) and from 150 ±
40% of control (H group) to 280 ± 40% of control (HS
group, p < 0.05 vs. H group, Figure 6B). After co-treatment
with SnPP, the relative increase of HO activity compared
to control decreased to 130 ± 20% (MSP group, p < 0.05
vs. the MS group, Figure 6A) and 110 ± 10% (HSP group,
p < 0.05 versus the HS group, Figure 6B). In MCT-PH rats,
the HO activities in the SnPP-treated rats (MSP and MP
groups) were not significantly different (p = 0.583 in MSP
group versus N group, p = 0.712 in MP group versus N
group, Figure 6A). These results show that simvastatin sig-
nificantly increased HO activity in PH rat lungs, and this
effect was blocked by co-administration of SnPP.
Discussion
In this study, we demonstrated that simvastatin treatment
decreased the pulmonary hypertension induced by MCT
or chronic hypoxia in rats via a mechanism which was
dependent on HO-1 activity. The main findings of this
study are as follows: (a) simvastatin could ameliorate pul-
monary hypertension in MCT-PH or CH-PH rats; (b) both
levels and activity of HO-1 were increased in rat lung after
simvastatin treatment; (c) the therapeutic effect of simvas-
tatin was abolished by inhibiting HO-1 enzyme activity
with SnPP, suggesting that the therapeutic effect of simv-
astatin is mediated by HO-1. This study demonstrated
that HO-1 activity plays a key role in the attenuation of
established pulmonary hypertension by simvastatin treat-
ment in PH rats. To our knowledge, this is the first study
to show that the decrease in severity of pulmonary hyper-
tension in rat lungs after simvastatin treatment depends
on the HO-1 enzyme activity rather than the level of HO-
1 protein expression.
Although numerous researchers prefer to use male ani-
mals for PH experiments to avoid any potential influence
of female hormones on the study results, we chose female
rats in this study for the potential application of simvasta-
tin in clinical use. Current literature describes nearly no
male-dominant tendencies in most clinical PH diseases in
humans.[22] In contrast, the incidence and prevalence of
idiopathic pulmonary arterial hypertension (PAH) and
secondary PAH related to connective tissue diseases in
human is higher in females than in males. [23-25] We
feel, therefore, that experimental results from female rats
are both clinically valid and necessary.
Previous reports have described that the beneficial effects
of simvastatin in preventing or reversing established PH
were observed over weeks of oral simvastatin administra-
tion.[8,26] In our study, significant attenuation of estab-
lished pulmonary hypertension was seen with treatment
times as short as three days, via intraperitoneal injection.
Although short duration oral simvastatin treatment may
also have the same effects as intraperitoneal injection, at
this point in time the short-term effects of oral simvastatin
on PH animals have not been examined. One reasonable
explanation for the prolonged treatment duration
required following oral simvastatin administration was
that the absorption and distribution of simvastatin were
slower than following intraperitoneal administration.
Although this intraperitoneal administration differs from
the more normal oral administration used in clinical set-
tings, our results still have valid clinical implications.
We examined the effects of simvastatin in two well-estab-
lished PH animal models, MCT- and CH-PH rats. MCT is
a pyrrolizidine alkaloid which is activated in the liver and
then transfers to the lungs causing pulmonary injury and
trauma.[27] In previous studies, pulmonary arterial
endothelial injury followed by an inflammatory response
triggered severe, progressive pulmonary hypertension, as
indicated by a dramatic increase in PAP and RVH.[28,29]
On the other hand, CH exposure leads to structural
changes in the pulmonary arteries, including smooth
muscle proliferation and hypertrophy, and produces well-
known adaptive PH changes in rat lungs. [30-33] Simvas-
tatin therapy can provide anti-inflammatory, anti-prolif-
erative, and pro-apoptotic effects and has been well
demonstrated to prevent or attenuate established PH in
several PH rat models. Simvastatin may restore eNOS
expression in endothelial cells, and can also attenuate PH
and inhibit pulmonary vascular remodelling in CHRespiratory Research 2009, 10:32 http://respiratory-research.com/content/10/1/32
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Western blot analysis of HO-1 protein expression in MCT-PH (A) and CH-PH (B) rat lung Figure 4
Western blot analysis of HO-1 protein expression in MCT-PH (A) and CH-PH (B) rat lung. Densitometric quanti-
fication revealed a significant increase in expression of HO-1 protein in the lungs of rats that received simvastatin and SnPP 
treatment. Densitometric units were normalized to β-actin and then divided by N group results. (N = normal control, NS = 
normal + simvastatin treatment, M = monocrotaline treatment, MS = monocrotaline + simvastatin treatment, MSP = monocro-
taline + simvastatin + SnPP treatment, MP = monocrotaline + SnPP treatment, H = chronic hypoxia, HS = chronic hypoxia + 
simvastatin treatment, HSP = chronic hypoxia + simvastatin + SnPP treatment, HP = chronic hypoxia + SnPP treatment).
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Immunohistochemical staining of the distribution of HO-1 in rat lung Figure 5
Immunohistochemical staining of the distribution of HO-1 in rat lung. Simvastatin treatment led to marked HO-1 
immunoreactivity around pulmonary vascular sites. (A) normal control, (B) MCT-PH rats, (C) CH-PH rats, (D) normal rats 
treated with simvastatin, (E) simvastatin treated, MCT-PH rats, (F) simvastatin treated, CH-PH rats. Magnification: 400×. Bars 
represent 20 μm.
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Changes in HO activity in MCT-PH (A) and CH-PH (B) rat lungs Figure 6
Changes in HO activity in MCT-PH (A) and CH-PH (B) rat lungs. Simvastatin treatment (MS and HS groups) signifi-
cantly increased HO activity compared with non-simvastatin treatment in PH rats (M and H groups). Co-administration of sim-
vastatin and SnPP (MSP and HSP groups) led to significantly less HO activity than in simvastatin-treated rats (MS and HS 
groups). The bilirubin concentration in each group was normalized to that of normal controls (Group N, value = 1.0). Horizon-
tal bars indicate groups that differed significantly from each other, * p < 0.05.
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rats.[34,35] In addition, simvastatin was able to rescue
rats from fatal PH by inducing apoptosis of vascular
neointimal smooth muscle cells in a pneumonectomy-
plus-MCT treatment rat model.[26] A recent study indi-
cated that simvastatin may ameliorate CH-PH by the inhi-
bition of ROCK expression and activity.[8] However, the
exact mechanism by which simvastatin mediates protec-
tion against PH has not yet been fully elucidated.
In the human body, heme oxygenase-1 (HO-1) degrades
heme to generate carbon monoxide (CO), iron, and
biliverdin, which is subsequently converted to bilirubin.
HO-1 is considered to be a cytoprotective enzyme because
each of these products of heme breakdown plays its own
protective role. Recent studies have found that inducible
HO-1 regulates vascular tone and cell proliferation
through the production of endogenous CO by the degra-
dation of heme.[36] CO activates guanylate cyclase, rais-
ing cellular cGMP level and resulting in vascular smooth
muscle relaxation.[37] Increasing evidence also suggests a
regulatory interaction in vascular smooth muscle cells
between CO and NO via HO-1, with HO-1 being regu-
lated by NO during hypoxia.[38,39] Lee et al. demon-
strated that the anti-inflammatory and anti-proliferative
effects of simvastatin were largely through the simvasta-
tin-induced HO-1 and the potential mechanism activat-
ing HO-1 expression may be through p38 and
phosphoinositide 3-kinase-Akt pathways.[16] Taken
together, we suggest that HO-1 may be crucial in the sim-
vastatin effects of attenuating PH.
There is other accumulating evidence that supports the
idea that HO-1 plays an important role in PH.[40] Lack of
HO-1 expression in HO-1-knockout mice was associated
with organized mural thrombi and subsequent PH; HO-1
transgenic mice were protected from the development of
vessel wall hypertrophy induced by CH.[14,41] HO-1
may play defensive roles against MCT-induced pulmonary
inflammation and cardiac hypertrophy in mice.[42]
Enhancement of endogenous HO-1 by NiCl2 or hemin
could prevent CH-PH.[13] Furthermore, previous studies
have shown that simvastatin induced HO-1 protein
expression in vascular smooth muscle cells [16] and
endothelial cells.[15] Microarray analysis revealed that
HO-1 was one of the genes with significantly increased
expression after simvastatin treatment in CH-PH rats.[43]
Zhou et al. showed that augmentation of endogenous
HO-1 by rapamycin treatment had antiproliferative and
vascular protective effects in MCT-PH.[44] These findings
indicate that the enhancement of HO-1 provides a thera-
peutic effect in experimental pulmonary hypertension.
Therefore, we proposed that the HO-1 pathway is
involved in simvastatin amelioration of pulmonary
hypertension. Our results confirm that induction of HO-
1 by simvastatin was responsible for attenuating effects on
PH and the severity of RVH in MCT- and CH-induced PH
rats.
In order to elucidate the important role of HO-1 in medi-
ating the protective effects of simvastatin, we co-adminis-
tered simvastatin with tin-protoporphyrin (SnPP), a
competitive antagonist of HO, in PH rats.[45] SnPP binds
to the catalytic sites of heme oxygenase to block the activ-
ity of HO proteins, thus permitting its use as a pharmaco-
logical agent for suppressing heme catabolism in animal
models.[46] Administration of simvastatin with SnPP sig-
nificantly decreased HO activity and thus successfully
abolished the therapeutic effects of simvastatin in PH rats.
Because HO-2 expression is constitutive and only HO-1
expression is inducible, it appears that simvastatin-
induced HO-1 protein expression is likely the main con-
tributor to the change of HO activity. Zhou et al. demon-
strated a similar effect of co-treatment with SnPP on
rapamycin-induced HO-1-mediated antiproliferative
effects in vascular disease.[44] Interestingly, although
SnPP administration in PH rats in the present study had
no beneficial effect on pulmonary hypertension, the pres-
ence of SnPP still significantly increased HO-1 protein
expression compared with that of untreated PH rats. This
phenomenon may be resulted from the dual mechanism
whereby SnPP regulates heme oxygenase – potently inhib-
iting the enzyme at the catalytic site by acting as a compet-
itive substrate for heme while enhancing the synthesis of
new enzyme protein[47]. Sardana et al. also demonstrated
that HO-1 levels increased strongly in rat liver after SnPP
application while HO-1 activity was significantly inhib-
ited.[47] Based on these findings, we hypothesize that
HO-1 activity rather than HO-1 protein over-expression is
the key factor underlying the beneficial effects of simvas-
tatin treatment in MCT- and CH-PH.
There were several limitations of this study. First, the
mechanism responsible for human PH remains to be elu-
cidated and our two animal models only partially mimic
the pathologic changes which occur in these conditions.
Therefore, it remains unclear whether the clinical benefits
of simvastatin in PH will be consistent with our results in
these animal models. Second, while we used a simvastatin
dose (10 mg/kgw) over a short duration (once daily treat-
ment for 3 days) which did effectively reduce the PAP in
PH rats, determination of the best dose and frequency of
simvastatin treatment in clinical applications requires fur-
ther investigation. Third, while we did not evaluate the
effect of simvastatin on pulmonary vascular remodelling
in PH rats because we did not anticipate any significant
change to the pulmonary vasculature in this short dura-
tion of simvastatin treatment, this also remains untested.Respiratory Research 2009, 10:32 http://respiratory-research.com/content/10/1/32
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Conclusion
This study demonstrated that simvastatin could attenuate
the severity of established PH in both MCT- and CH-PH
rat models and that the mechanism underlying this bene-
ficial effect is mediated by HO-1 activity rather than
expression.
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